Roffman Miller Associates Inc. PA Buys 2,953 Shares of Johnson & Johnson $JNJ

Roffman Miller Associates Inc. PA lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 266,371 shares of the company’s stock after buying an additional 2,953 shares during the quarter. Johnson & Johnson comprises 2.4% of Roffman Miller Associates Inc. PA’s portfolio, making the stock its 15th largest position. Roffman Miller Associates Inc. PA’s holdings in Johnson & Johnson were worth $40,688,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $218,000. Smart Money Group LLC lifted its holdings in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company’s stock valued at $1,109,000 after purchasing an additional 407 shares during the last quarter. Argyle Capital Management LLC boosted its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Argyle Capital Management LLC now owns 26,004 shares of the company’s stock worth $4,313,000 after purchasing an additional 200 shares in the last quarter. Finally, Element Wealth LLC grew its stake in shares of Johnson & Johnson by 5.8% in the first quarter. Element Wealth LLC now owns 1,886 shares of the company’s stock worth $313,000 after acquiring an additional 104 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.4%

NYSE:JNJ opened at $186.24 on Tuesday. The company has a market cap of $448.71 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a 50 day simple moving average of $183.43 and a two-hundred day simple moving average of $167.96. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. Research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Citigroup lifted their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Finally, Raymond James Financial increased their target price on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $199.05.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.